Praed is developing PPL-201 for the treatment of Crohn’s disease. PPL-201 was discovered by Actelion and has concluded a Phase III clinical program in another gastro-intestinal indication. The compound’s safety profile as well as all CMC (chemistry, manufacturing, and controls) are well established. Praed in-licensed PPL-201 from Actelion, which became part of the Janssen Pharmaceutical Companies of Johnson & Johnson in 2017. PPL-201 enjoys a strong data and patent protection.
MAP (Mycobacterium avium ssp. paratuberculosis) infections are implicated as the cause of Crohn’s disease. PPL-201 is not only highly active against MAP but has also demonstrated to be well tolerated in a separate Phase II/III development program with 684 patients against an intestinal infection with C. difficile. We believe that PPL-201 could be effective in the treatment of Crohn’s disease.
We are planning, initiating, and conducting a Phase 2a clinical study – results expected in three years’ time – for which we are currently raising funds.
Crohn’s disease is a chronic, inflammatory bowel disease, which is debilitating and incurable. Current treatments address symptoms and disease progression but patients are progressing relentlessly, nevertheless. Today, patients sooner or later receive therapy with biologicals.